Extracellular vesicles (EVs) are known to be involved in intercellular communication during cancer progression; thus, elucidating the detailed mechanism will contribute to the development of a novel strategy for EV-targeted cancer treatment. However, the biogenesis of EVs in cancer cells is not completely understood. MicroRNAs (miRNAs) regulate a variety of physiological and pathological phenomena; thus, miRNAs could regulate EV secretion.
shown that EVs play important roles in tumor progression . Indeed, in prostate cancer (PCa), some reports have shown that EVs contribute to drug resistance or progression of metastasis 4 5 6 .
Recently several reports have shown the potential that a reduction in cancer-derived EVs shows therapeutic value by inhibiting cancer proliferation and dissemination 3 . For instance, HER2 expressed on the surface of breast cancer-derived EVs has been shown to interfere with therapy and is associated with cancer progression 7 . In addition, Marleau et al. described a therapeutic strategy for the removal of circulating EVs by developing a hemofiltration system to capture HER2-positive EVs miRNAs that are involved in EV secretion. To perform screening of nearly 2000 species of miRNAs, we used our established EV detection method, ExoScreen, which can directly detect EVs in conditioned medium based on an amplified luminescent proximity homogeneous assay 12 . We comprehensively screened miRNAs using a miRNA library and found that miR-26a, which was reported as a tumor suppressive miRNA in PCa 12 13 , negatively regulates EV secretion in PCa cells. In addition, we identified three target genes that were involved in EV secretion in PCa cells. Furthermore, reduced expression of miR26a and upregulation of target genes were shown in PCa tumors compared with normal
tissues. An in vivo study demonstrated that reduced expression of these three genes inhibited PCa tumor growth, and this change was partially rescued by the injection of EVs from PCa cells. These results suggest novel insight into miRNA-mediated tumor suppression through inhibiting EV biogenesis, which may provide novel approaches for PCa treatment.
Results

Establishment of a high-throughput compatible extracellular vesicle biogenesis assay
The PC3M cells were seeded in 96-well plates and transfected with each miRNA mimic.
Twenty-four hours after transfection, the medium was changed to serum-free medium and then incubated for another 48 hours. After that, we collected the conditioned medium 14 to evaluate the EV level by ExoScreen, which can directly detect EVs based on an amplified luminescent proximity homogeneous assay using photosensitizer beads and two specific antigens residing on EVs 12 ( Figure 1A ). We confirmed that EVs derived from PC3M were CD9-and CD63-positive by immunoblotting ( Figure 1B) ; therefore, we used CD9 to detect the change in EV secretion in this first screen. In addition, to exclude the effect of miRNAs on cellular proliferation, we performed a colorimetric MTS assay, as shown in Figure 1A . To assess the quality of transfection in each plate, several controls were used, and the effectiveness of siRNA controls on EV secretion was almost the same between the plates and validated the quality of transfection (Supplementary Figure 1A) . The EV secretion was calculated by the ExoScreen assay and MTS assay, and the values were evaluated as the fold change relative to the negative control.
Quantitative high-throughput analysis of candidate miRNAs in prostate cancer cells
A miRNA mimic library was screened to investigate the modulatory effects of various kinds of miRNAs on EV biogenesis. We evaluated the effectiveness of each miRNA on the secretion of EVs by ExoScreen and cell proliferation by colorimetric MTS assays. We selected miRNAs according to the criteria shown in Figure 1C . We performed screenings three times and chose 58 miRNAs. After excluding miRNAs whose number was higher than 2000, we selected 30 miRNAs ( Figure 1C ). Next, to further validate our initial screening, we assessed the secretion of CD63-positive EVs and CD9 and CD63 double-positive EVs by ExoScreen in these 30 miRNAs ( Figure 1A) . In this set, we selected miRNAs that showed the relative value of EV secretion/cell viability, evaluated by the ExoScreen assay and MTS assay, which was lower than 0.8. Since the relative value of EV secretion/cell viability by silencing TSG101, which is known to regulate the biogenesis of EVs Figure 1B) , we expected that the miRNAs could suppress the secretion of EVs, similar to TSG101. Then, we chose miR-26a and miR-194 as candidate miRNAs to regulate EV secretion ( Figure 1D ). To select miRNAs that can clinically regulate EV secretion, we investigated a public database (GSE 21036). Principal component analysis (PCA) maps with 373 miRNAs suggested that the miRNA profiles differed between the PCa and normal adjacent benign prostate tissues (Supplementary Figure 2A) . Additionally, as shown in a heat map displaying the 59 differentially expressed miRNAs, which were repressed more than 1.25-fold in prostate cancer tissue relative to normal adjacent benign prostate tissue and had a p-value less than 0.001, there were obvious differences in miRNA expression, including miR-26a, although we could not find a difference in the expression of miR-194 in prostate cancer tissue relative to normal adjacent benign prostate tissue ( Figure 1E and Supplementary Figure 2B ). These results suggest that miR-26a is involved in EV secretion of PCa. Furthermore, we confirmed that the particle number of EVs secreted by each PCa cell transfected with the miR-26a mimic was also decreased using ExoScreen and nanoparticle trafficking analysis (NTA) ( Figure 1F , G and Supplementary Figure 2C , D). Therefore, we selected miR-26a for further or detailed analysis and investigated whether miR-26a regulates EV secretion in prostate cancer.
Selection of candidate genes regulating extracellular vesicle secretion in prostate cancer cells
miRNAs are known to regulate hundreds of mRNA targets, providing global changes in the cellular phenotype of cells 16 . To further elucidate the molecular mechanisms of miR-26a in EV secretion, we identified the target genes of miR-26a. We performed mRNA microarray analysis in PC3M and PC3 after the transfection of miR-26a mimic or control. For the genes that could be targeted by miR-26a picked up by TargetScan, we found that overexpression of miR-26a in prostate cancer cells downregulated 88 genes compared with the control cells by miRNA expression (Figure 2A ). Then, to select genes regulating EV secretion, we performed high-throughput screening using ExoScreen again. The PC3M cells were seeded in a 96-well plate and transfected with each candidate siRNA of the 88 genes. Twenty-four hours after transfection, the medium was changed to serum-free medium for 48 hours of incubation. From the transfected PC3M cells, we collected the conditioned medium to evaluate the EV levels by ExoScreen and MTS assays ( Figure 2B ). We evaluated CD9-positive EVs and CD63-positive EVs by ExoScreen. The criteria of the selected genes are described in Figure 2C . The results of each screening are shown in Supplementary Figure 3 .
Finally, we identified four genes, SHC4, PFDN4, CHORDC1 and PRKCD, as candidate genes regulating EV secretion ( Figure 2C ).
SHC4, PFDN4 and CHORDC1 regulate extracellular vesicle secretion in prostate cancer.
Next, we confirmed the effect of these genes on the secretion of EVs derived from prostate cancer cells after treatment with siRNA for these genes. The EV levels secreted by each prostate cancer cell were decreased after transfection with the siRNAs of the three genes, SHC4, PFDN4 and CHORDC1, indicating that these genes are regulators of EV secretion Figure 3A) . Then, to address whether miR-26a directly regulated these genes, we performed a luciferase reporter assay ( Figure 3B ). Ectopic expression of miR-26a significantly suppressed the luciferase activity of the wild-type SHC4, PFDN4 and CHORDC1 3'-UTRs but not their mutant 3'-UTRs ( Figure 3C ). These results provide experimental evidence that miR-26a can directly repress translation initiation of SHC4, PFDN4 and CHORDC1, and the downregulation of miR-26a promoted EV secretion. Additionally, using a public database (GSE6099), we investigated the expression levels of these genes in prostate cancer tissue.
We confirmed that the expression levels of PFDN4 and CHORDC1 were significantly upregulated in prostate cancer tissue compared to normal tissue ( Figure 3D ).
PFDN4, SHC4 and CHORDC1 regulate EV secretion and promote tumorigenesis in vivo
miR-26a was shown to suppress the tumor formation of prostate cancer; thus, this antitumor activity could be because of the suppression of EV secretion from prostate cancer cells by miR-26a. 17 19 . To confirm the role of these genes targeted by miR-26a in prostate cancerderived EVs, we performed in vivo experiments. Initially, we established a PC3M cell line with stable SHC4, PFDN4 or CHORDC1 depletion by using each short-hairpin RNA and evaluated the common aspects of tumorigenesis. Depletion of these genes repressed EV secretion ( Figure 4A ). We assessed the effect of SHC4, PFDN4 and CHORDC1 downregulation in this model and found that mice bearing PC3M xenografts with depletion of these genes had smaller tumors that weighed less than those of control mice ( Figure 4B , C).
In addition the tumor tissues of nude mice injected with PC3M-derived EVs showed partially rescued tumor size and weight ( Figure 4D and Supplementary Figure 6) . The above data suggest a signaling network that links miR-26a with its targets SHC4, PFDN4, and CHORDC1 and demonstrated the novel mechanism of miR-26a-regulated EV secretion in prostate cancer ( Figure 5 ).
Discussion
Although EVs have been reported to modulate cancer progression for approximately ten , and VPS4
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, have been implicated in EV secretion. In addition, we
showed that neutral sphingomyelinase-2 (nSMase2), which is required for the synthesis of ceramide, regulates EV secretion in breast cancer . However, the downregulation of nSMase2 did not inhibit EV secretion in PCa . These data suggest that the biogenesis of EV secretion is different between each kind of cancer. In addition, to establish a novel therapeutic strategy for PCa by inhibiting EV secretion, the mechanism of PCa-specific EV secretion should be revealed.
In the present study, based on a comprehensive miRNA analysis, we showed that miR-26a
and miR-194 regulate the secretion of EVs in PCa. We focused on miR-26a because the expression level of miR-26a was reduced in PCa tissue compared to normal prostate tissue.
Previous studies have demonstrated the suppressive role of miR-26a in prostate cancer growth 17 19 , and our study has reported the novel role of miR-26a. That is, miR-26a not only inhibits tumorigenesis but also prevents the secretion of EVs. As mentioned above, suppression of EV secretion could be a novel therapeutic strategy. Therefore, these data suggest that miR-26a represents a potential therapeutic target to treat the progression of prostate cancer by inhibiting EV communication.
miRNAs are known to regulate hundreds of mRNA targets, providing global changes in the cellular phenotype of cells 16 . To investigate the target genes of miR-26a that suppress EV secretion, we performed high-throughput screening and selected four candidate genes, PRKCD, SHC4, PFDN4 and CHORDC1. Although the knockdown of PRKCD in PCa decreased the secretion of total EVs, it significantly decreased PCa cell proliferation.
Therefore, the secretion of EVs by each cell was not decreased. PRKCD is implicated in the growth, migration and invasion of cancer cells, including PCa
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; therefore, downregulation of PRKCD in PCa cells was critical for cell viability.
We revealed that miR-26a directly targets SHC4, PFDN4 and CHORDC1, and downregulation of these genes suppressed the secretion of EVs in PCa. Although we did not report the precise mechanism of these genes in regulating EV secretion in the present study, several articles have suggested a relationship between EV biogenesis and these genes. Rab-11 contributes to the endocytic pathway through transportation of the endocytosed cargo to the endocytic recycling compartment 27 . In addition, Rab11 was found to be essential for EV secretion 28 . These data suggest that ShcD may also affect the endocytic pathway and contribute to EV secretion. Morgana, which is coded by the CHORDC1 gene, binds to the and CHORDC1, much less is known about the function of PFDN4. The PFDN4 gene is a transcriptional factor regulating the cell cycle 31 . In breast cancer, PFDN4 was found to play a role in cancer behavior; however, biological analysis remains to be performed 32 . The precise mechanism by which these genes in EV secretion should be investigated in a future study; however, our data suggest, for the first time, that SHC4, PFDN4 and CHORDC1
contribute to EV secretion in prostate cancer and could be novel therapeutic targets.
Additionally, in vivo experiments showed that knocking down these genes decreased tumor progression at the primary site. Although we could not confirm that the tumor suppressive effect was only caused by the inhibition of EV secretion, the tumor xenografts of nude mice injected with PC3M-derived EVs partially rescued the tumor size and weight of the genedepleted PC3M xenografts. SHC4, PFDN4 and CHORDC1 are expected to be beneficial for the inhibition of cell proliferation and cell-to-cell communication via EVs in PCa.
In summary, our study extensively screened miRNAs that regulate exosome secretion in PCa and found that miR-26a regulates EV secretion by targeting SHC4, PFDN4 and CHORDC1. This finding reveals novel insight into miRNA-mediated tumor suppression by inhibiting EV biogenesis, which may provide novel approaches for PCa treatment.
Materials and Methods
Reagents
The following antibodies were used as primary antibodies in immunoblotting: mouse monoclonal anti-human CD9 antibody (clone 12A12, dilution 1:1000) and CD63 antibody (clone 8A12, dilution 1:1000) from Cosmo Bio (Tokyo, Japan). Rabbit polyclonal anti-human PFDN4 (16045-1-AP, dilution 1:200) was from the Proteintech Group. Mouse monoclonal anti-human SHC4 (clone 2F5, dilution 1:300) was from Sigma-Aldrich. Rabbit polyclonal antihuman CHORDC1 (NBP1-78304, dilution 1:2500) was purchased from Novus Biologicals (Littleton, CO). Secondary antibodies (horseradish peroxidase-linked anti-mouse IgG, NA931, or horseradish peroxidase-linked anti-rabbit IgG, NA934, dilution 1:5000) were purchased from GE Healthcare.
The following antibodies were used for ExoScreen analysis: mouse monoclonal anti-human CD9 antibody (clone 12A12) and CD63 antibody (clone 8A12). These antibodies were used to modify either acceptor bead or biotin following the manufacturer's protocol.
The following miRNA mimic or siRNA was used for the transient transfection assay: miR-26a
(4464058), TSAP6 siRNA (4392422), Rab27a siRNA (S11693), Rab27b siRNA (S11697), and nSMase2 siRNA (S30925) were purchased from Ambion (Austin, TX, USA). ALL STAR negative control siRNA (SI03650318) and TSG101 siRNA (SI02655184) were purchased from Qiagen (Hilden, Germany). PFDN4 siRNA (siGENOME SMART pool siRNA M-013012), SHC4 siRNA (siGENOME SMART pool siRNA M-031768), CHORDC1 siRNA (siGENOME SMART pool M-019998) and PRKCD siRNA (siGENOME SMART pool M-003524) were purchased from Dharmacon (Lafayette, CO, USA).
Cell culture
The human prostate cancer epithelial metastatic cell line PC3 (ATCC CRL-1435) was purchased from ATCC. PC3 and PC-3M-luc-C6 (PC3M) (Xenogen, Alameda, CA) were cultured in RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and an antibiotic-antimycotic (Gibco) solution at 37°C. For routine maintenance, each cell line was grown as a monolayer at 37°C with 5% carbon dioxide and 95% relative humidity (RH).
Preparation of conditioned media and extracellular vesicles
The cells were washed with phosphate-buffered saline (PBS), and the culture medium was replaced with advanced RPMI 1640 medium (Gibco) for PC3M and PC3, containing an antibiotic-antimycotic and 2 mM L-glutamine (Gibco) . EVs from the conditioned medium were isolated by a differential ultracentrifugation protocol, as we previously reported 34 . Briefly, the conditioned medium was centrifuged at 2,000xg for 10 min to remove contaminating cells.
The resulting supernatants were then transferred to fresh tubes and filtered through a 0.22 µm filter (Millipore). The filtered conditioned medium was centrifuged for 70 min at 110,000x
g to pellet the enriched EVs (Beckman Coulter, Brea, CA, USA). The pellets were washed with 11 ml of PBS and ultracentrifuged at 110,000xg for another 70 min. The EV pellets were stored in a refrigerator at 4°C until use.
Immunoblotting
The EV fraction or the transfected PCa cells was measured for protein content using the Negative Control #1, Ambion) was used at a final concentration of 10 nM to investigate the effect of miR-26a on EV secretion. PFDN4 siRNA, CHORDC1 siRNA, SHC4 siRNA, PRKCD siRNA or ALL STAR negative control siRNA was used at a final concentration of 10 nM to investigate the effect of these genes on EV secretion. After 24 hours, the conditioned medium was changed to Advanced RPMI medium containing an antibiotic-antimycotic and 2 mM Lglutamine. Forty-eight hours after the medium change, total RNA was extracted using a miRNeasy Mini Kit (Qiagen) according to the manufacturer's instructions, and PFDN4, CHORDC1 and SHC4 expression were then determined by qPCR. The CM was collected and purified for EVs by ultracentrifugation.
Analysis of extracellular vesicle particles by nanoparticle tracking analysis
Isolated EV suspensions diluted in PBS were analyzed by NanoSight particle tracking analysis (LM10, with software version 2.03). For particle tracking, at least five 60 sec videos were taken of each sample with a camera gain of 7. The analysis settings were optimized and kept constant between samples. EV concentrations were calculated as particle/cell of culture to obtain net vesicle secretion rates.
Microarray and bioinformatics
To perform a mRNA microarray, 1.0x10 5 PC3M and PC3 cells were seeded into 6-well plates, and 24 hours later, the transfection of miR-26a mimic or controls was accomplished with the DharmaFECT Transfection Reagent 1 (Dharmacon) according to the manufacturer's protocol.
After 24 hours, the CM was changed to Advanced RPMI medium containing 2 mM Lglutamine without an antibiotic-antimycotic. Total mRNAs were extracted from the PC3M and PC3 cells 48 hours after the medium change.
Total RNA was amplified and labelled with Cy3 using a Low Input Quick Amp Labeling Kit, one color (Agilent Technologies), following the manufacturer's instructions. Briefly, 100 ng of total RNA was reverse-transcribed to double-stranded cDNA using a poly dT-T7 promoter primer. Primer, template RNA and quality-control transcripts of known concentration and quality were first denatured at 65 °C for 10 min and incubated for 2 h at 40 °C with 5 × first- 
RNA extraction and qPCR analysis
Total RNA was extracted from cultured cells using QIAzol and the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocols. The purity and concentration of all RNA samples were quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). The reverse transcription reaction was performed using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and a random hexamer primer. Real-time PCR analyses were performed using StepOne Plus and TaqMan Universal PCR Master Mix (Thermo Fisher Scientific). Expression of mRNA was normalized to b-actin.
TaqMan probes for PFDN4, SHC4, CHORDC1 and b-actin were purchased from Applied Biosystems.
Construction of shRNA vector and establishment of stable cell lines
Knockdown vectors expressing shRNAs were constructed by subcloning an annealed oligonucleotide into the pBAsi-hU6-Pur vector (TaKaRa Bio). Oligonucleotide sequences encoding the shRNA hairpin are shown below. 
Plasmid constructs and luciferase reporter assay
The following annealed oligos (Thermo Fisher) were used for constructing 3'UTR-reporter The annealed oligo for the 3′UTR of PFDN4, SHC4, or CHORDC1 was subcloned into psiCHECK2 that had been digested with XhoI and NotI. To mutate miR-26a recognition sites in PFDN4, SHC4, or CHORDC1, annealed oligos were used. Mice were monitored carefully, and the size of their tumors was measured using a Vernier caliper. Tumors were harvested 31 days after inoculation of cancer cells, and tumor weight was measured.
Statistical analysis
Unless otherwise described, the data are presented as the mean±SE, and statistical significance was determined by Student's t-test. In the dot plot, the bars indicate the median and interquartile range, and statistical significance was determined by Student's t-test.
P<0.05 was considered statistically significant. 
